Serious infections such as emerging and re-emerging infectious diseases and multidrug-resistant infections are spreading globally with unprecedented speed, alongside an increasingly interconnected world brought about by the development of the global economy. Shionogi continues to discover superior drugs for these bacterial, fungal and viral infections through our strengths in biomedical research and small molecule drug discovery. Furthermore, we are making proactive efforts in research for drugs to treat multidrug-resistant tuberculosis and neglected tropical diseases by participating in the Global Health Innovative Technology Fund (GHIT), a public-private-partnership initiative.
Trojan Horse: The discovery of a new antibiotic, Cefiderocol (S-649266)
The Infectious Disease Research Group led by Yoshinori Yamano at Shionogi is making vigorous efforts to tackle drug-resistant bacteria, and has discovered the new antibiotic cefiderocol (S-649266) which has been shown to demonstrate potent efficacy against infections caused by multidrug-resistant Gram-negative bacteria.
Towards suppression of HIV: The development of dolutegravir
There have been efforts at Shionogi for over 20 years to develop anti-HIV agents that can continue to be taken safely while maintaining anti-HIV activity, and which have seen the successful development of the groundbreaking HIV integrase inhibitor, dolutegravir.